The world has turned its attention to COVID-19, but deadly viruses such as Zika, malaria and Hepatitis C also need our support to find treatments and cures.
Did you know malaria kills 400,000 children a year?
Nearly 120,000 babies are born each year with a Zika birth defect. And there are four million new Hepatitis C infections each year, including 10,000 in Australia.
That’s why The Hospital Research Foundation Group is proud to be a longtime supporter of research into virology and infection control which plays an important role in protecting our global communities.
Developing a world-first vaccine for the Zika virus, sourcing a novel needle-free delivery for the vaccine, and taking important steps to progress to Phase 1 clinical trials in patients.
Dr Branka Grubor-Bauk’s world-leading work aims to help prevent Zika infection in pregnant women, which can result in severe birth defects in infants born to infected mothers.
Discovering a new target for treating malaria which involves targeting enzymes from the human host, rather than the parasite itself.
Dr Danny Wilson and his collaborators are now looking to existing cancer drug discoveries with the hope of repurposing a drug that is already, or soon will be, available for use in people, to help treat deadly malaria.
Running pre-clinical studies on the effectiveness of a new Hepatitis C virus (HCV) vaccine.
Dr Makutiro Masavuli’s project is examining the protective efficacy of the vaccine, which aims to lead to human clinical trials and the opportunity to further develop the vaccine to prevent HCV infection in the community.
Funding numerous projects and clinical trials into immunology, vaccine development, treatments, ventilator technology and more for COVID-19.
Dr Branka Grubor Bauk (pictured) and Professor Simon Barry have been leading South Australian based COVID-19 research, and were one of the first research groups in the world to present findings on immunity one year after infection.